trending Market Intelligence /marketintelligence/en/news-insights/trending/Qy3Dh7MXgU7aSIWG-ahAQw2 content esgSubNav
In This List

Theratechnologies wins EU approval for HIV drug Trogarzo

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Theratechnologies wins EU approval for HIV drug Trogarzo

Theratechnologies Inc. said the European Commission granted marketing authorization for its HIV drug Trogarzo to treat adult patients with multidrug-resistant infection.

Trogarzo is administered into a vein once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. The drug attaches to the CD4+ protein molecules on host cells and blocks the HIV virus from infecting the cells. Antiretroviral drugs are medications that do not kill or cure the HIV virus but can slow down or prevent its growth.

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended Trogarzo's approval in July.

The U.S. Food and Drug Administration granted approval for Trogarzo in March 2018.

Montreal-based Theratechnologies acquired the commercialization rights to Trogarzo in the U.S., the EU, Canada, Israel, Norway, Russia and Switzerland from TaiMed Biologics Inc.